Despite near-term headwinds from subscription pivot and CEO transition, the company demonstrates strong fundamentals: 21% ARR growth, 80%+ gross margins, 16% net profit margin, market leadership with 7,000 customers including government agencies, and FedRAMP authorization. The analyst predicts a five-year rebound outperforming the S&P 500, citing AI growth potential and customer stickiness, though execution risks and high valuation (47.58 P/E) require monitoring.
Cellebrite DI news
About Cellebrite DI
Featured as a key player in the high-growth digital forensics sector, particularly in mobile device forensics which is identified as a major market trend.
The article is a routine regulatory announcement regarding the filing of the annual report. There is no new business information, financial results, or strategic developments disclosed that would indicate positive or negative sentiment. It is a standard procedural disclosure required by securities regulations.
Also mentions CLBT
Articles that tag CLBT but are mainly about other companies.
Modest 0.9% gain in last session with minimal monthly return of 0.6%. While EPS estimates show 21.4% YoY growth, the stock carries a Zacks Rank #4 (Sell) rating, indicating limited upside potential.
21% annual recurring revenue growth, 32% free cash flow margin, 83.86% gross margin, successful transition to subscription model, strong government contracts, and new Genesis AI product expected to drive future growth.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology